Search results
Your search for process/pmg6 returned no results
Showing 436 to 450 of 2854 results for process
Showing 436 to 450 of 2854 results for process
This quality standard covers the clinical care of adults (aged 18 and over) who are dying, during the last 2 to 3 days of life. It describes high-quality care in priority areas for improvement.
People can comment on our guidance at specific stages in its development.
People can comment on our guidance at specific stages in its development.
Ibrutinib for treating relapsed or refractory follicular lymphoma [ID1251]
In development Reference number: GID-TA10223 Expected publication date: TBC
In development Reference number: GID-TA10227 Expected publication date: TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]
In development Reference number: GID-TA10225 Expected publication date: TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]
In development Reference number: GID-TA10313 Expected publication date: TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development Reference number: GID-TA10573 Expected publication date: TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development Reference number: GID-TA10623 Expected publication date: TBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]
In development Reference number: GID-TA10832 Expected publication date: TBC
Awaiting development Reference number: GID-TA10885 Expected publication date: TBC
In development Reference number: GID-TA10205 Expected publication date: TBC
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Awaiting development Reference number: GID-TA10682 Expected publication date: TBC
In development Reference number: GID-TA10326 Expected publication date: TBC
In development Reference number: GID-TA10542 Expected publication date: TBC